{"paper_id":"b4ca006b-ec7e-483a-8d53-3bf3bd685967","body_text":"Lycopene is a red carotenoid\npigment known for its strong antioxidant\nproperties and health benefits. Structurally, it is a linear hydrocarbon\n(C 40 H 56 ) with 13 double bonds, 11 of which are\nconjugated.  ( Figure  \n ).\nChemical structure of lycopene and β-carotene.\nIt exists predominantly in the all- trans  isomeric\nform in raw foods, but thermal processing (e.g., cooking tomatoes)\nconverts it into  cis -isomers, which are more bioavailable\nand readily absorbed in human tissues. Dietary sources of lycopene\nare abundant and include tomatoes, watermelon, pink grapefruit, papaya,\nguava, and rosehips. Among these, tomatoes and tomato-based products\n(such as sauces, juices, and pastes) account for over 80% of lycopene\nintake in Western diets.  As one of the\nmost potent dietary antioxidants, its molecular structure enables\nefficient quenching of singlet oxygen and scavenging of free radicals,\nthereby reducing oxidative stress that damages lipids, proteins, and\nDNA. In addition to antioxidant activity, lycopene exerts strong anti-inflammatory\neffects by modulating cytokine profiles and key signaling pathways,\ncounteracting the chronic inflammation underlying atherosclerosis,\ndiabetes, cancer, and autoimmune disorders.  It also influences hormonal balance and metabolic regulation, particularly\nin obesity, metabolic syndrome, and type 2 diabetes, where insulin\nresistance and lipid dysregulation are central features.  Beyond these roles, lycopene interacts with transcription\nfactors and signaling cascades that govern cell proliferation, apoptosis,\ndifferentiation, and immune responses, underscoring its broad impact\non cellular function. Together, these mechanisms highlight lycopene’s\nmultifaceted bioactivity in maintaining health and reducing the risk\nof noncommunicable diseases.\n\nLycopene exerts\nsignificant cardioprotective effects by improving lipid metabolism\nand supporting vascular function. It reduces low-density lipoprotein\n(LDL) cholesterol by binding to LDL particles and preventing oxidative\nmodification, a key step in atherosclerosis development. Lycopene\nalso lowers total cholesterol and triglycerides by inhibiting HMG-CoA\n(3-hydroxy-3-methylglutaryl-coenzyme A) reductase and upregulating\nhepatic LDL receptors, thereby enhancing lipid clearance. While high-density\nlipoprotein (HDL) levels are not markedly increased, its functionality\nimproves through enhanced antioxidant capacity and reverse cholesterol\ntransport. Beyond lipid regulation, lycopene combats atherosclerosis\nand endothelial dysfunction by reducing vascular inflammation, preserving\nnitric oxide bioavailability, and improving vasodilation. These combined\nactions reflect a systems-level modulation of cardiovascular health,\nencompassing lipid profiles, blood pressure, and vascular integrity.\nRegular consumption of lycopene-rich foodssuch as tomatoes,\nwatermelon, and guavawithin diets rich in antioxidants and\nanti-inflammatory compounds, like the Mediterranean diet, has been\nconsistently associated with reduced cardiovascular morbidity and\nmortality.\nLycopene exhibits strong anticancer activity by suppressing uncontrolled\ncell proliferation, inducing apoptosis, and modulating key signaling\npathways. It halts tumor growth through cell cycle arrest at G1/S\nand G2/M checkpoints, downregulating cyclins and CDKs while upregulating\ninhibitors such as p21 and p27. Apoptosis is promoted via mitochondrial\nand death receptor pathways, with increased levels of Bcl-2-associated\nX protein (Bax), reduced levels of B-cell lymphoma 2 (Bcl-2), and\nactivation of caspases. Lycopene also inhibits nuclearfactor kappa-light-chain-enhancer\nof activated B cells (NF-κB), lowering pro-inflammatory cytokines,\nand impedes angiogenesis and metastasis by downregulating vascularendothelialgrowthfactor\n(VEGF) and matrixmetalloproteinases (MMPs). Beyond these intrinsic\neffects, lycopene enhances conventional cancer therapies. It sensitizes\ntumor cells to chemotherapy agents, mitigates oxidative stress in\nnormal tissues, and supports radiation therapy by reducing ROS-induced\ndamage (ROS: reactive oxygen species). In hormone-sensitive cancers,\nit improves outcomes by modulating receptor signaling, while its immunomodulatory\nactionssuch as boosting natural killer cell activitymay\ncomplement immunotherapy. Collectively, these mechanisms highlight\nlycopene’s dual role as both a direct anticancer agent and\na synergistic adjunct to established treatments.\nLycopene plays a multifaceted role in combating metabolic disorders\nsuch as obesity, type 2 diabetes, and metabolic syndromeconditions\ndriven by oxidative stress, inflammation, and insulin resistance.\nIts antioxidant and anti-inflammatory properties reduce ROS and pro-inflammatory\ncytokines, improving adipose tissue function. Lycopene also modulates\nadipokines by normalizing leptin and enhancing adiponectin, thereby\nimproving insulin sensitivity and reducing inflammation. It suppresses\nadipogenesis through downregulation of transcription factors like\nperoxisome proliferator-activated receptor γ (PPARγ) and\nCCAAT/Enhancer-Binding Protein α (C/EBPα), while favorably\ninfluencing lipid metabolism by lowering triglycerides and LDL cholesterol\nand enhancing HDL functionality. At the hormonal level, lycopene enhances\ninsulin signaling via insulinreceptorsubstrate (IRS) activation andphosphoinositide3-kinase/protein\nkinase B (PKB) (PI3K/Akt) pathways, reduces IRS-1 phosphorylation,\nand activates Sirtuin 1 (SIRT1) to improve mitochondrial efficiency\nand metabolic flexibility. These combined effects contribute to better\nglucose uptake, energy balance, and protection against age-related\ninsulin resistance. Collectively, lycopene emerges as a promising\ndietary compound for regulating metabolism and reducing the burden\nof obesity and diabetes.\nLycopene\nsupports fertility in both men and women by counteracting oxidative\nstress and restoring hormonal balance. In males, supplementation improves\nsperm concentration, motility, and morphology by protecting spermatozoa\nfrom ROS damage and enhancing Leydig cell function, which sustains\ntestosterone production. It also safeguards the hypothalamic–pituitary–gonadal\naxis, helping regulatefollicle-stimulatinghormone (FSH) andluteinizinghormone\n(LH) for effective spermatogenesis.  In\nfemales, lycopene protects ovarian follicles from oxidative injury,\nimproves oocyte quality, and balances estrogen and progesterone levels\nthat are essential for ovulation and endometrial receptivity. Its\nanti-inflammatory and antiandrogenic effects benefit conditions such\nas endometriosis and polycysticovarysyndrome (PCOS), where it enhances\ninsulin sensitivity, lowers excess androgens, and promotes regular\ncycles. Evidence from animal and in vitro studies further supports\nits role in improving ovarian morphology, follicular development,\nand granulosa cell function.  Collectively,\nlycopene emerges as a promising modulator of reproductive health through\nits antioxidant, anti-inflammatory, and endocrine-regulating activities.\nThe brain’s\nhigh oxygen demand and lipid content make it vulnerable to oxidative\nstress, a key driver of neuronal death, inflammation, and neurodegenerative\ndiseases such as Alzheimer’s (AD) and Parkinson’s (PD).\nLycopene protects neural tissues by neutralizing free radicals, enhancing\nendogenous antioxidant enzymes, and reducing lipid peroxidation, DNA\ndamage, and protein oxidation. It activates PI3K/Akt and nuclear factor\nerythroid 2–related factor 2 (Nrf2) pathways to promote cell\nsurvival, suppress apoptosis, and strengthen antioxidant defenses,\nwhile inhibiting nuclear Factor kappa-light-chain-enhancer of activated\nB cells (NF-κB) signaling and supporting brain-derivedneurotrophicfactor\n(BDNF) expression for neuronal repair and synaptic maintenance. In\nAD, lycopene reduces amyloid-β aggregation, preserves mitochondrial\nintegrity, and downregulates pro-inflammatory cytokines, thereby limiting\nneuronal apoptosis and improving synaptic function. In PD, it attenuates\ndopamine oxidation, restores mitochondrial activity, and reduces apoptosis\nthrough the modulation of Bax/Bcl-2 and caspase-3. Preclinical studies\nshow improved cognition, motor coordination, and reduced neuroinflammation,\nwhile observational data link higher lycopene levels to lower AD mortality.\nIts ability to cross the blood–brain barrier (BBB) and accumulate\nin neural tissues underscores lycopene’s promise as a dietary\nneuroprotective agent and adjunct therapy for neurodegenerative disorders.\nLycopene demonstrates promising antiviral and immunomodulatory\nproperties, making it a potential adjunct in managing viral infections\nsuch as SARS-CoV-2, HIV, HPV, and hepatitis C. Its antiviral effects\ninclude disrupting viral entry, suppressing RNA synthesis, and modulating\nhost signaling pathways such as NF-κB and mitogen-activatedproteinkinase\n(MAPK), thereby reducing replication efficiency and protecting host\ncells from oxidative damage. In COVID-19, lycopene may help prevent\ncytokine storms by lowering Interleukin-6 (IL-6) and tumornecrosisfactor\nα (TNF-α), while preserving lung tissue integrity and\nreducing oxidative stress. Equally important are its immunomodulatory\nactions, which fine-tune both innate and adaptive immunity. Lycopene\nenhances macrophage phagocytosis, supports NK cell activity, and promotes\nbalanced T and B cell responses while reducing excessive cytokine\nrelease through NF-κB and MAPK inhibition and strengthening\nantioxidant defenses via Nrf2 activation. Evidence from preclinical\nand clinical studies suggests that lycopene supplementation can restore\nimmune balance, lower inflammation, and improve recovery from respiratory\ninfections. Safe at doses of 15–45 mg/day, and with bioavailability\nenhanced by dietary fats and heat processing, lycopene emerges as\na safe, multifunctional compound with potential to support antiviral\ndefense and immune resilience.\nLycopene has emerged as a powerful ally in preserving eye health.\nUnlike other carotenoids such as β-carotene, lycopene does not\nconvert into vitamin A, but its potent antioxidant properties make\nit uniquely effective in combating oxidative stressa major\ncontributor to age-related eye diseases. The eyes, constantly exposed\nto light and environmental toxins, are particularly vulnerable. Lycopene\nhelps neutralize these free radicals, protecting delicate eye tissues\nsuch as the retina and lens from degeneration. This protection is\nespecially critical in preventing conditions such as age-related macular\ndegeneration (AMD) and cataracts, both of which are leading causes\nof vision loss in older adults. Liu et al.  investigated the protective effects of lycopene against corneal\nendothelial damage, a condition driven by oxidative stress from environmental\nfactors and genetic mutations. While lycopene is recognized as a potent\nnatural antioxidant, its role in corneal endothelial health has remained\nunclear. Using an oxidative stress-induced injury model in a human\ncorneal endothelial cell line (B4G12 cells) and a genetically engineered\nmouse model of Fuchs’ endothelial corneal dystrophy (FECD),\nthe study demonstrated that lycopene effectively preserved corneal\nendothelial cells and slowed disease progression. Mechanistically,\nlycopene upregulated P62 and activated autophagy, promoting Keap1\ndegradation, facilitating Nrf2 nuclear translocation, and enhancing\nthe expression of downstream antioxidant proteins. These findings\nhighlight lycopene’s potential as a nonsurgical therapeutic\napproach for preventing or mitigating corneal endothelial damage.\nAlabdulmunem  investigated the protective\neffects of lycopene in the context of diabetic retinopathy, a leading\ncause of vision loss among individuals with diabetes. Oxidative stress\nhas been widely recognized as a central contributor to the pathogenesis\nof both diabetes and its retinal complications. Epidemiological evidence\nindicates that diets rich in carotenoid-containing fruits and vegetables\nare associated with a reduced risk of diabetes-related complications,\nincluding retinopathy. In this study, the antioxidant potential of\nlycopene was evaluated using D407 retinal pigment epithelial (RPE)\ncells through incorporation studies and the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium\nbromide) cell cytotoxicity assay. Lycopene demonstrated robust antioxidant\nactivity  in vitro  and exhibited no cytotoxic effects\non Retinal Pigment Epithelium (RPE) cells. These findings suggest\nthat lycopene may serve as a promising agent to slow or prevent the\nprogression of diabetic retinopathy by mitigating oxidative stress\nwhile maintaining cellular safety. Recent studies have shown that\nlycopene supplementation can enhance macular pigment density, which\nshields the retina from harmful blue light and supports visual acuity\nand contrast sensitivity. Additionally, lycopene’s anti-inflammatory\nproperties help reduce chronic inflammation in the eyes, which is\nlinked to conditions like uveitis and dry eye syndrome.  By inhibiting pro-inflammatory cytokines, lycopene\nnot only alleviates symptoms but also contributes to long-term eye\nresilience.  Compared to other eye-supporting\ncarotenoids such as lutein and zeaxanthin, lycopene offers complementary\nbenefits. While lutein and zeaxanthin concentrate in the macula, lycopene’s\nbroader antioxidant activity supports the entire ocular system. This\nmakes it a valuable addition to any eye health regimen, through either\ndiet or supplementation. Incorporating lycopene-rich foods into daily\nmeals is a simple yet effective strategy. \n Table  \n  summarizes\nthe mechanisms of action, advantages, and existing limitations of\nlycopene for various diseases.\n\nLycopene faces several bioavailability challenges that limit its\ntherapeutic potential. One major issue is its poor water solubility;\nlycopene is highly lipophilic and virtually insoluble in water, which\nhampers its absorption in the gastrointestinal tract. In aqueous environments,\nit tends to aggregate and crystallize, further reducing its bioaccessibility.  Additionally, lycopene is extremely sensitive\nto environmental stressors, such as light (leading to photooxidation),\noxygen (causing autoxidation), and heat (triggering thermal isomerization).\nThese factors collectively contribute to the degradation of lycopene,\nresulting in the loss of color, potency, and biological activity during\nprocessing and storage.  Another complication\narises from isomerization: while the all- trans  form\nis predominant in raw foods, it is less bioavailable compared to the  cis -isomers. However, although food processing can increase\nthe proportion of  cis -isomers and thereby improve\nabsorption, these forms tend to be less chemically stable. Biological\nbarriers also impede lycopene’s effectiveness, including enzymatic\ndegradation in the gastrointestinal tractparticularly by β-carotene\noxygenasesand limited transport across the intestinal epithelium\ndue to its poor solubility and the lack of specific carrier proteins.\nTogether, these factors significantly constrain lycopene’s\nsystemic availability and therapeutic efficacy.\nNanoencapsulation has emerged as a powerful strategy\nto overcome lycopene’s physicochemical limitations. These systems\nprotect lycopene from degradation, enhance solubility, and improve\nbioavailability.  Nanoformulations have\nemerged as an effective strategy to improve the stability, bioavailability,\nand delivery of lycopene. Various encapsulation materials are employed,\nincluding natural polymers such as chitosan, alginate, and gelatin;\nsynthetic polymers like PLGA (poly­(lactic- co -glycolic\nacid)), PEG (polyethylene glycol), and PCL (polycaprolactone); and\nproteins such as whey protein isolate, sodium caseinate, and pea protein.  Surfactants such as Tween 20 and lecithin are\nalso commonly used to stabilize formulations. One of the major advantages\nof nanoencapsulation is its role in enhancing lycopene stability.\nThe encapsulation matrix acts as a physical barrier, protecting lycopene\nfrom environmental stressors such as oxygen, light, and heat.  Additionally, emulsifiers and surfactants help\nstabilize the nanodispersion by preventing particle aggregation, and\ncoencapsulation with antioxidants like vitamin E can further enhance\nprotection. Several optimization parameters are critical in nanoformulation\ndesign: smaller particle sizes tend to improve intestinal absorption;\nzeta potential values greater than ±30 mV indicate strong electrostatic\nrepulsion and good colloidal stability; encapsulation efficiency reflects\nthe percentage of lycopene successfully enclosed within the carrier;\nand the release profile determines how lycopene is gradually delivered\nover time, which is crucial for maintaining therapeutic levels.\nTargeted delivery systems for lycopene are designed to enhance\ntherapeutic efficacy by directing the compound to specific tissues\nor cells, thereby maximizing its biological effects while minimizing\nsystemic side effects. These systems utilize a range of targeting\nstrategies. Passive targeting takes advantage of the enhanced permeability\nand retention (EPR) effect commonly seen in tumor tissues, allowing\nnanoparticles to accumulate more readily in these areas. In contrast,\nactive targeting employs specific ligandssuch as folic acid\nor antibodiesthat bind to receptors overexpressed on target\ncells.  Additionally, stimuli-responsive\nsystems have been developed, enabling lycopene release in response\nto environmental triggers such as pH changes, temperature shifts,\nor the presence of specific enzymes. To further improve therapeutic\ncontrol, controlled-release mechanisms are incorporated, including\ndiffusion-controlled systems (where lycopene gradually diffuses through\na matrix), erosion-controlled systems (where matrix degradation leads\nto release), and swelling-controlled systems (in which environmental\nchanges cause the matrix to expand and release its contents).  One example is lycopene-loaded PLGA nanoparticles,\nwhich have demonstrated 3- to 9-fold higher bioaccessibility than\nfree lycopene, sustained release over a 12-day period, and non-Fickian\ndiffusion kineticssuggesting a complex and efficient release\nprofile.  Moreover, organ-specific delivery\nof lycopene using nanocarriers has been successfully achieved, targeting\nthe liver for hepatoprotective effects, the prostate for anticancer\napplications, the brain for neuroprotection, and the skin for anti-inflammatory\nand photoprotective benefits. \n Table  \n  compares key parameters\nsuch as encapsulation efficiency, release profiles, and targeting\ncapabilities across these different systems.\nEnhanced lycopene formulations have shown promising results in\nboth preclinical and clinical studies. Human trials have demonstrated\nthat lycopene nanoemulsions can significantly improve plasma concentrations\nand the levels of antioxidant markers. Additionally, encapsulated\nlycopene has been observed to reduce prostate-specific antigen (PSA)\nlevels in men with benign prostatic hyperplasia, while liposomal lycopene\nformulations exhibit superior skin penetration and help mitigate UV-induced\ndamage. \n , \n  From a pharmacokinetic perspective, nanoformulations\nenhance the absorption rate, increase the peak plasma concentration\n( C \n max ), and improve the area under the\ncurve (AUC), with controlled release systems maintaining therapeutic\nlevels over extended periods. At the molecular level, lycopene interacts\nwith various targets, including nuclear receptors such as PPARγ\nand RAR, G protein-coupled receptors (GPCRs), and ion channels. Computational\npharmacology studies have further identified mitogen-activated protein\nkinase kinase 2 (MAP2K2), sodium voltage-gated channel alpha subunit\n2 (SCN2A), and tripartite motif containing 24 (TRIM24) as high-affinity\ntargets for lycopene. In terms of safety, most lycopene nanoformulations\nare biocompatible and nontoxic, with long-term studies reporting no\nadverse effects at therapeutic doses. However, regulatory approval\nfor these formulations depends on their specific type and intended\napplication.\nSmart delivery systems\nfor lycopene, such as thermoresponsive polymers such as Poly­( N -isopropylacrylamide)–poly­(ethylene glycol) (PNIPAAM–PEG),\nenable temperature-triggered release, while pH-sensitive carriers\ntarget the tumor microenvironment more effectively. Hybrid systems\nthat combine lycopene with other bioactive compounds, including curcumin\nand resveratrol, offer synergistic therapeutic effects through coencapsulation\nstrategies aimed at multitarget therapy.  Personalized nutrition approaches are emerging, tailoring lycopene\nformulations based on individual genetic factors that influence absorption\nand integrating these formulations into functional foods and beverages.\nFrom a regulatory and commercial perspective, the market for lycopene-based\nsupplements and fortified foods is expanding, but there remains a\ncritical need for standardized protocols in encapsulation methods\nand stability testing.  Additionally,\nclinical trials are essential to validate the efficacy and safety\nof these products across diverse populations. In conclusion, while\nlycopene’s therapeutic potential is vast, its clinical utility\ndepends on overcoming challenges related to bioavailability and stability.\nAdvances in nanoformulations, encapsulation technologies, and targeted\ndelivery systems have markedly improved lycopene’s pharmacokinetic\nprofile and therapeutic efficacy, facilitating its application in\ndisease prevention and treatment, paving the way for its role in personalized\nmedicine and functional nutrition.\n\nLycopene is generally considered safe when consumed through food\nsources and exhibits a favorable toxicological profile. It is nonmutagenic,\nnoncarcinogenic, and does not accumulate in tissues to toxic levels.\nBoth animal and human toxicity studies consistently show a low risk,\neven at high doses.  Regarding acute toxicity,\nno lethal dose (LD 50 ) has been established due to lycopene’s\nlow toxicity; animal studies administering doses up to 1000 mg/kg\nbody weight reported no adverse effects. Chronic exposure studies\nin rats and mice also revealed no significant organ damage or carcinogenicity\nwith prolonged supplementation. While some safety data sheets mention\na possible risk of impaired fertility or harm to the unborn child\nat extremely high concentrations, such effects have not been observed\nat dietary or therapeutic levels.  Lycopene\nmay act as a moderate irritant to the skin and eyes in its pure form,\nbut no allergic reactions have been reported from dietary lycopene,\nalthough rare hypersensitivity to tomato-based products may occur.  The observed safe level (OSL) for adults is\nup to 75 mg per day, with wide safety margins as therapeutic doses\nremain well below toxic thresholds. Additionally, lycopene is nonhazardous\nfor transport and does not require special handling under normal conditions.\nLycopene dietary intake varies widely depending on individual diet,\nwith average consumption in Western diets ranging from 3 to 10 mg\nper day.  Rich sources of lycopene include\nraw tomatoes, which contain approximately 3.1 mg per 100 g, tomato\nsauce with 33–68 mg per 100 g, and ketchup at about 3.3 mg\nper tablespoon.  Other fruits, such as\nwatermelon, pink grapefruit, and guava, provide between 3 and 8 mg\nper serving. Therapeutic doses of lycopene, often delivered via supplements,\nare typically higher. General supplementation of 15–45 mg per\nday for up to six months is considered safe. In the context of prostate\ncancer support, doses between 10 and 30 mg per dayor up to\n43 mg per day from tomato-based productshave shown benefits\nin stabilizing PSA levels.  For cardiovascular\nand antioxidant support, 10–20 mg of daily doses has been found\nto improve lipid profiles and oxidative stress markers, while doses\nof 10–15 mg per day enhance skin photoprotection by increasing\nUV resistance and reducing erythema. Because lycopene is lipophilic,\nits absorption improves when consumed with dietary fats, and processed\ntomato products such as paste and juice offer better bioavailability\nthan raw tomatoes due to isomerization into more absorbable  cis -forms. Supplement forms include softgels, capsules,\nand nanoemulsions, which may further enhance absorption. No serious\nadverse effects have been reported at therapeutic doses, though mild\ngastrointestinal symptoms such as nausea, diarrhea, or bloating may\noccur in sensitive individuals. Excessive intake can lead to lycopenodermia,\na harmless condition characterized by orange discoloration of the\nskin.\nLycopene is widely recognized and regulated as a safe food additive\nacross multiple regions. In the United States, the FDA (U.S. Food\nand Drug Administration) approves lycopene as a color additive under\n21 CFR §73.585 for use in foods, with tomato lycopene extract\nand concentrate exempt from certification due to their established\nsafety profile. It can be used broadly in foods, except where standards\nof identity prohibit added color, and must comply with Good Manufacturing\nPractices (GMP) and labeling requirements outlined in §70.25.  In the European Union, lycopene is listed as\nE160d and permitted as a food colorant in products such as beverages,\ndairy, confectionery, and supplements, with maximum levels varying\nby product category.  The European Food\nSafety Authority (EFSA) has reviewed lycopene’s safety and\nconcluded that it poses no safety concerns at typical intake levels.  Internationally, Codex Alimentarius and the\nWorld Health Organization recognize lycopene as a safe food additive\nand antioxidant, including it in global food standards for coloring\nand fortification, and have not established an acceptable daily intake\n(ADI) due to its low toxicity. In countries such as Japan and China,\nlycopene is approved for use in functional foods and supplements,\nregulated under local food safety laws and labeling requirements,\nand commonly marketed for skin health, antioxidant support, and cardiovascular\nbenefits. Regarding labeling and health claims, any assertions must\nbe supported by clinical evidence, with lycopene supplements often\npromoted for heart health, prostate support, skin protection, and\nantioxidant defense. Labels are required to specify the source, such\nas tomato extract, dosage, and any contraindications.  In conclusion, lycopene is a well-tolerated, widely consumed\ncarotenoid with a robust safety profile and broad regulatory acceptance.\nWhile dietary intake typically provides modest levels, therapeutic\nsupplementation offers enhanced benefits for cardiovascular, reproductive,\nand skin health. Advances in formulation have improved its bioavailability,\nand global regulatory agencies have approved its use in foods and\nsupplements with minimal restrictions. As research continues to explore\nlycopene’s therapeutic potential, its safety, versatility,\nand regulatory clarity make it a valuable component of modern nutrition\nand preventive medicine.\n\nDespite promising preclinical data and epidemiological associations,\ntranslating these benefits into consistent clinical outcomes has proven\nto be challenging. Several limitations and research gaps hinder lycopene’s\nfull integration into evidence-based therapeutic protocols. These\ninclude variability in clinical results, lack of standardized formulations\nand dosing, and a scarcity of long-term human trials.  While numerous studies suggest that lycopene may reduce\nthe risk of chronic diseases such as prostate cancer, cardiovascular\ndisease, and metabolic syndrome, clinical outcomes remain inconsistent.\nSome trials report significant improvements in biomarkers, whereas\nothers show negligible or no effects. These discrepancies arise from\nmultiple sources. Heterogeneous study designsdiffering in\npopulation demographics, sample sizes, and measured end pointsmake\ncross-study comparisons difficult, and the source of lycopene varies\nwidely across studies, with interventions ranging from raw tomatoes\nand tomato paste to supplements and synthetic formulations, each with\ndistinct bioavailability profiles. The duration of intervention is\nanother critical variable; short-term studies may not fully capture\nlycopene’s therapeutic potential.  Dietary confounders, including the baseline diet and lifestyle habits,\nare often insufficiently controlled and may obscure true effects.\nA notable example is prostate health research, where some clinical\ntrials have shown reductions in PSA levels and tumor volume following\nlycopene supplementation, while others report no significant changes\ndespite increased serum lycopene concentrations.  These inconsistencies may reflect differences in formulation,\ndosage, and patient risk profiles, as well as biological variability\nin absorption, metabolism, and tissue distribution. Genetic polymorphisms\naffecting carotenoid transport and metabolism may further modulate\nindividual responses to supplementation.  Additionally, variability in biomarker selectionranging\nfrom oxidative stress markers to inflammatory cytokines and lipid\nparameterslimits comparability across studies and may not\nalways align with lycopene’s primary mechanisms of action.\nTo address these issues, future clinical studies should adopt standardized,\nhigh-bioavailability formulations; harmonize dosing regimens; employ\nunified and mechanistically relevant biomarker panels; and stratify\nparticipants based on baseline lycopene status, metabolic health,\nand genetic background. Incorporating pharmacokinetic assessments,\nextending study durations, and improving control of dietary and lifestyle\nconfounders will further strengthen the reliability of clinical findings\nand help clarify lycopene’s true therapeutic potential.\nThere is a notable lack of uniformity in how lycopene is administered\nacross studies with various formulations including capsules, softgels,\nemulsions, and food-based matrices. These differ significantly in\nisomer composition ( trans vs .  cis  forms), carrier oils and excipients, particle size, and delivery\nsystems, making it difficult to compare outcomes across clinical trials.  Dosing further complicates the landscape: typical\ndietary intake ranges from 3 to 15 mg/day in Western diets, while\nsupplemental doses can vary widely from 10 to 75 mg per day. Currently,\nthere is no established Recommended Dietary Allowance (RDA) for lycopene.  Moreover, bioavailability may plateau at doses\nbetween 10 and 30 mg, beyond which absorption shows diminishing returns.\nAnalytical standardization presents another challenge. Although methods\nsuch as reverse-phase high-performance liquid chromatography (RP-HPLC)\nand spectrophotometry are used to quantify lycopene in supplements\nand foods, inconsistencies in extraction and measurement techniques\nhinder reliable dose–response evaluations.  The formulation of lycopene significantly influences its\nbioavailability. Processed tomato products like paste and sauce, for\nexample, offer superior absorption compared with raw sources due to\nheat-induced isomerization. Emerging technologies such as nanoformulations\nand encapsulation methods, including liposomes and PLGA nanoparticles,\nhave demonstrated improved stability and absorption. However, these\nadvanced delivery systems remain unstandardized across clinical studies,\nfurther complicating the interpretation of efficacy data.\nMost\nhuman studies of lycopene focus on short-term interventions lasting\nweeks to a few months, leaving long-term safety, efficacy, and disease-modifying\neffects largely unexplored. Many trials suffer from small sample sizes,\nlimiting their power to detect meaningful clinical outcomes, and few\ninclude follow-up periods to assess sustained benefits or potential\nadverse effects over years. Additionally, most studies rely on surrogate\nmarkerssuch as oxidative stress levels or PSArather\nthan hard clinical outcomes like disease incidence or mortality.  In cancer prevention trials, particularly for\nprostate cancer, systematic reviews reveal mixed results, underscoring\nthe need for long-term studies to clarify lycopene’s potential\nto reduce cancer incidence or progression.  Preclinical research suggests neuroprotective effects of lycopene,\nbut human trials remain scarce and short-term, with longitudinal studies\nneeded to determine its role in cognitive aging and neurodegenerative\ndiseases such as AD and PD. In cardiovascular health, lycopene has\nbeen shown in short-term studies to lower LDL cholesterol and improve\nendothelial function; however, long-term trials are necessary to establish\nits impact on major cardiovascular events such as heart attacks and\nstrokes. Overall, while lycopene holds significant promise as a bioactive\ncompound with broad health benefits, clinical translation is hindered\nby inconsistent trial outcomes driven by variability in study design,\ndosing, and formulation; a lack of standardized delivery systems and\nanalytical methods; and insufficient long-term human data to support\ndisease prevention claims. To advance lycopene from a promising phytonutrient\nto a validated therapeutic agent, rigorous large-scale randomized\ncontrolled trials using standardized formulations, consensus on optimal\ndosing and bioavailability-enhancing strategies, and longitudinal\nstudies assessing sustained efficacy and safety are essential.\n\nIts full therapeutic potential remains underutilized due to challenges\nin bioavailability, formulation, and clinical translation. As research\nadvances, new technologies and strategies are reshaping how lycopene\nis delivered, personalized, and integrated into preventive healthcare.\nAs mentioned above, lycopene is highly lipophilic and unstable when\nexposed to light, heat, and oxygen, which limits its effectiveness.\nTo address these challenges, researchers are developing advanced delivery\nsystems that protect lycopene and enhance its absorption.  Key innovations include nanoemulsionsoil-in-water\nemulsions with droplet sizes under 200 nm that improve solubility\nand gastrointestinal uptakeand liposomes, which are phospholipid\nvesicles that encapsulate lycopene, offering biocompatibility and\ncontrolled release. Solid lipid nanoparticles (SLNs) provide high\nloading capacity and protect lycopene from oxidation, while biodegradable\npolymeric nanoparticles such as PLGA enable targeted delivery and\nsustained release.  These technologies\nnot only increase bioavailability but also allow site-specific delivery\nto organs such as the liver, prostate, or brain, enabling disease-specific\napplications. In parallel, green extraction methods are advancing\nlycopene production with higher purity and sustainability. Techniques\nsuch as pulsed electric fields (PEF) enhance extraction yield and\nantioxidant activity with minimal energy use; ultrasound-assisted\nextraction improves recovery while reducing solvent consumption; and\nsupercritical CO 2  extraction offers a solvent-free, efficient\nprocess suitable for pharmaceutical-grade lycopene.  These approaches align with green chemistry principles\nand support clean-label product development. Moreover, smart controlled-release\nsystems are being designed to release lycopene in response to physiological\ntriggers, such as pH-sensitive carriers that activate in acidic tumor\nmicroenvironments, thermoresponsive polymers that release lycopene\nat elevated temperatures found in inflamed tissues, and enzyme-responsive\nsystems that activate in the presence of disease-specific enzymes.  These smart delivery platforms enable precision\ndosing, minimize side effects, and enhance therapeutic outcomes.\nPersonalized medicine increasingly leverages individual genetic,\nmetabolic, and lifestyle data to tailor interventions, and lycopene’s\nrole in this paradigm is gaining attention, particularly in chronic\ndisease prevention.  Genetic factors such\nas polymorphisms in carotenoid metabolism genes like β-Carotene\n15,15’-Monooxygenase 1 (BCMO1) and Scavenger Receptor Class\nB Member 1 (SCARB1) influence lycopene absorption and tissue distribution,\nmeaning individuals with reduced bioavailability may require higher\ndoses or enhanced formulations. Metabolic conditions including obesity,\ndiabetes, and aging are associated with lower plasma lycopene levels\nand impaired tissue uptake, highlighting the need for personalized\ndosing strategies to compensate for these metabolic impairments.  Advances in computational pharmacology have\nidentified lycopene’s molecular targetssuch as MAP2K2,\nSCN2A, and TRIM24which show variable expression across tissues.\nNetwork pharmacology approaches further reveal that lycopene modulates\ninterconnected signaling pathways involving nuclear receptors, G protein-coupled\nreceptors (GPCRs), and ion channels, supporting targeted supplementation\nbased on individual disease risk and molecular profiles. Additionally,\nemerging evidence suggests that lycopene can beneficially influence\nthe gut microbiota by enhancing populations of probiotics such as  Lactobacillus  and  Bifidobacterium  while\nreducing pro-inflammatory species linked to metabolic and immune disorders.\nThis microbiome modulation opens the door for personalized lycopene\ninterventions aimed at optimizing gut–brain axis function,\nimmune support, and metabolic health.\nLycopene is increasingly incorporated into functional foods, such\nas enriched yogurts, cereals, and beverages, providing convenient\ndelivery methods that promote disease prevention and overall wellness.\nIt is also utilized in sports nutrition products for its antioxidant\nand anti-inflammatory benefits, supporting lifestyle-based prevention,\nparticularly for cardiovascular and metabolic disorders.  Beyond individual use, lycopene’s preventive\npotential is being explored in population health contexts, where it\nhas demonstrated improvements in endothelial function and reductions\nin LDL oxidation relevant to cardiovascular disease, associations\nwith lower risks of prostate, breast, and digestive cancers, and protective\neffects on skin against UV damage as well as support for bone density.\nIntegrating lycopene into dietary guidelines and public health campaigns\noffers promising avenues to reduce the disease burden and healthcare\ncosts. Clinically, although lycopene is not yet mainstream, its use\nis advancing as an adjunct in prostate cancer management and cardiovascular\nrisk reduction, included in personalized supplement regimens for high-risk\nindividuals, and monitored via serum levels to assess antioxidant\nstatus and dietary adequacy.  Future protocols\nmay incorporate lycopene in preventive panels, especially for aging\npopulations and those experiencing chronic inflammation. Overall,\nlycopene is undergoing a transition from a dietary antioxidant to\na precision health tool. Emerging delivery technologies like nanoencapsulation\nand smart carriers are improving its stability, bioavailability, and\ntherapeutic reach, while personalized medicine approaches tailor its\nuse based on genetics, metabolism, and microbiome profiles. As research\ncontinues to refine these innovations, lycopene is poised to become\na cornerstone of next-generation nutrition and preventive medicine,\neffectively bridging the gap between food and pharmaceuticals.\n\nLycopene, a naturally occurring\ncarotenoid abundant in tomatoes,\nwatermelon, pink grapefruit, and other red fruits, has emerged as\na powerful bioactive compound with diverse therapeutic applications.\nIts unique molecular structure, containing 11 conjugated double bonds,\nconfers exceptional antioxidant capacity, enabling it to neutralize\nreactive oxygen species more effectively than other carotenoids, such\nas β-carotene and α-tocopherol. This antioxidant potency\nunderpins lycopene’s broad biological effects across multiple\norgan systems and disease states. Preclinical and clinical studies\ndemonstrate its efficacy in cancer prevention and therapy by inhibiting\ncell proliferation, inducing apoptosis, and modulating signaling pathways\nsuch as phosphoinositide 3-kinase/protein kinase B/mechanistic target\nof rapamycin (PI3K/Akt/mTOR), NF-κB, and insulin-like growth\nfactor-1 (IGF-1), particularly in prostate, breast, colon, and skin\ncancers. Lycopene also provides cardiovascular protection by lowering\nLDL cholesterol, improving endothelial function, and reducing atherosclerotic\nplaque formation, while its metabolic benefits include enhancing insulin\nsensitivity, modulating adipokines, and reducing oxidative stress\nin metabolic syndrome, obesity, and type 2 diabetes. Neuroprotective\neffects are evident in its ability to shield neurons from oxidative\ndamage, preserve mitochondrial function, and mitigate neurodegenerative\ndiseases such as Alzheimer’s and Parkinson’s. In reproductive\nhealth, lycopene improves sperm quality, regulates sex hormones, and\nprotects reproductive tissues from oxidative and inflammatory damage.\nEmerging evidence further highlights its antiviral activity, including\nthe inhibition of viral replication such as SARS-CoV-2 and modulation\nof immune responses. These multifaceted effects position lycopene\nas a compelling candidate for integrative disease prevention and adjunctive\ntherapy, with its safety profile, natural origin, and dietary availability\nenhancing its appeal as a functional nutrient.\nDespite this\npromise, clinical translation faces challenges due\nto lycopene’s poor water solubility, chemical instability,\nand variable bioavailability. Advances in formulation scienceincluding\nnanoencapsulation, liposomal delivery, and polymeric carriershave\nimproved its pharmacokinetic properties, while computational pharmacology\nand systems biology approaches have identified high-affinity molecular\ntargets such as MAP2K2, SCN2A, and TRIM24, supporting its role as\na multitarget therapeutic agent. Translational potential is further\nstrengthened by tissue-specific delivery systems, controlled-release\ntechnologies, and synergistic combinations with other bioactives or\nconventional therapies, bridging the gap between bench and bedside.\nLooking ahead, future research should prioritize precision nutrition\napproaches that integrate genomics, metabolomics, and microbiome profiling\nto identify the individuals most likely to benefit from lycopene-based\ninterventions. Such personalized strategies may help explain interindividual\nvariability in absorption and response, enabling tailored dosing and\nformulation selection. Additionally, multifunctional combination therapiespairing\nlycopene with other antioxidants, phytochemicals, or standard pharmacotherapiesrepresent\na promising direction for enhancing efficacy through complementary\nmechanisms of action.\nTo fully realize lycopene’s therapeutic\npotential, standardized\nformulations, optimized dosing regimens, and robust long-term clinical\ntrials remain essential. Interdisciplinary collaboration will be critical:\npharmacologists and formulation scientists must develop stable, bioavailable\ndelivery systems; molecular biologists and computational scientists\nshould continue elucidating mechanisms and molecular targets; clinicians\nand epidemiologists need to conduct well-controlled, longitudinal\nstudies; and nutritionists and public health experts should integrate\nlycopene into dietary guidelines and preventive health strategies.\nResearch priorities include the development of validated biomarkers\nfor absorption and therapeutic response, exploration of gene–nutrient\ninteractions, and evaluation of lycopene within precision health frameworks\nthat combine lifestyle, dietary, and molecular data. Ultimately, lycopene\nrepresents a paradigm shift in the use of dietary compounds for therapeutic\npurposes. Its potent antioxidant and anti-inflammatory properties,\ncoupled with disease-specific efficacy, make it a valuable tool against\nchronic illness. While challenges remain, the convergence of technological\ninnovation, molecular insight, and personalized healthcare strategies\noffers a clear path forward. With rigorous research and translational\ndevelopment, lycopene can evolve from a promising phytonutrient into\na cornerstone of integrative and precision medicine, bridging nutrition,\npharmacology, and public health for a healthier future.","source_license":"CC-BY-4.0","license_restricted":false}